HM-61713 free base · Synonyms: BI-1482694 | Olmutinib | (1802181-20-9)

Olmutinib is an orally active and irreversible third EGFR tyrosine kinase inhibitor.

For research use only. Not for human or veterinary use.

Target EGFR

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

HM-61713 structure

CAS No.: 1353550-13-6

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
500 mg	USD 498.00	BP-02482-500mg	In stock	Get quote
1 g	USD 810.00	BP-02482-1g	In stock	Get quote
2 g	USD 1,300.00	BP-02482-2g	In stock	Get quote
3 g	USD 1,560.00	BP-02482-3g	In stock	Get quote
5 g	USD 2,070.00	BP-02482-5g	In stock	Get quote
10 g	USD 3,320.00	BP-02482-10g	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Description

Olmutinib (HM61713; BI-1482694) is an orally active and irreversible third EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib is used for NSCLC .

Biological activity

In Vitro Olmutinib potently inhibits EGFR in HCC827 cells expressing EGFRDEL19 (IC50=9.2 nM) and H1975 cells expressing EGFRL858R/T790M (IC50=10 nM). In contrast, the IC50 of olmutinib against cells expressing EGFRWT is 2225 nM.

Identifiers

SMILES: CN1CCN(CC1)C1=CC=C(NC2=NC(OC3=CC(NC(=O)C=C)=CC=C3)=C3SC=CC3=N2)C=C1
InChIKey: FDMQDKQUTRLUBU-UHFFFAOYSA-N

Specifications

MW (average): 486.5890
Formula: C₂₆H₂₆N₆O₂S
CAS No.: 1353550-13-6
Physical state: Solid
Color: Light yellow to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 year;

Solubility

Soluble in DMSO

Documents

References

[1]. Kim ES, et al. Olmutinib: First Global Approval. Drugs. 2016 Jul;76(11):1153-7.

[2].Mohamed W. Attwa, et al. Detection and characterization of olmutinib reactive metabolites by LC‐MS/MS: Elucidation of bioactivation pathways. Journal of Separation science. 18 November 2019.

Same target

Search EGFR

Same research area

Search Cancer